Loading…

CD19-CAR T cells undergo exhaustion DNA methylation programming in patients with acute lymphoblastic leukemia

CD19-CAR T cell therapy has evolved into the standard of care for relapsed/refractory B cell acute lymphoblastic leukemia (ALL); however, limited persistence of the CAR T cells enables tumor relapse for many patients. To gain a deeper understanding of the molecular characteristics associated with CA...

Full description

Saved in:
Bibliographic Details
Published in:Cell reports (Cambridge) 2021-11, Vol.37 (9), p.110079-110079, Article 110079
Main Authors: Zebley, Caitlin C, Brown, Charmaine, Mi, Tian, Fan, Yiping, Alli, Shanta, Boi, Shannon, Galletti, Giovanni, Lugli, Enrico, Langfitt, Deanna, Metais, Jean-Yves, Lockey, Timothy, Meagher, Michael, Triplett, Brandon, Talleur, Aimee C, Gottschalk, Stephen, Youngblood, Ben
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:CD19-CAR T cell therapy has evolved into the standard of care for relapsed/refractory B cell acute lymphoblastic leukemia (ALL); however, limited persistence of the CAR T cells enables tumor relapse for many patients. To gain a deeper understanding of the molecular characteristics associated with CAR T cell differentiation, we performed longitudinal genome-wide DNA methylation profiling of CD8 CD19-CAR T cells post-infusion in ALL patients. We report that CAR T cells undergo a rapid and broad erasure of repressive DNA methylation reprograms at effector-associated genes. The CAR T cell post-infusion changes are further characterized by repression of genes (e.g., TCF7 and LEF1) associated with memory potential and a DNA methylation signature (e.g., demethylation at CX3CR1, BATF, and TOX) demarcating a transition toward exhaustion-progenitor T cells. Thus, CD19-CAR T cells undergo exhaustion-associated DNA methylation programming, indicating that efforts to prevent this process may be an attractive approach to improve CAR T cell efficacy.
ISSN:2211-1247
2211-1247
DOI:10.1016/j.celrep.2021.110079